• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过使用全自动微阵列平台进行特定序列捕获,对癌症相关外显子亚组进行靶向高通量测序。

Targeted high throughput sequencing of a cancer-related exome subset by specific sequence capture with a fully automated microarray platform.

机构信息

febit biomed gmbh, Im Neuenheimer Feld 519, 69120 Heidelberg, Germany.

出版信息

Genomics. 2010 Apr;95(4):241-6. doi: 10.1016/j.ygeno.2010.01.006. Epub 2010 Feb 6.

DOI:10.1016/j.ygeno.2010.01.006
PMID:20138981
Abstract

Sequence capture methods for targeted next generation sequencing promise to massively reduce cost of genomics projects compared to untargeted sequencing. However, evaluated capture methods specifically dedicated to biologically relevant genomic regions are rare. Whole exome capture has been shown to be a powerful tool to discover the genetic origin of disease and provides a reduction in target size and thus calculative sequencing capacity of >90-fold compared to untargeted whole genome sequencing. For further cost reduction, a valuable complementing approach is the analysis of smaller, relevant gene subsets but involving large cohorts of samples. However, effective adjustment of target sizes and sample numbers is hampered by the limited scalability of enrichment systems. We report a highly scalable and automated method to capture a 480 Kb exome subset of 115 cancer-related genes using microfluidic DNA arrays. The arrays are adaptable from 125 Kb to 1 Mb target size and/or one to eight samples without barcoding strategies, representing a further 26 - 270-fold reduction of calculative sequencing capacity compared to whole exome sequencing. Illumina GAII analysis of a HapMap genome enriched for this exome subset revealed a completeness of >96%. Uniformity was such that >68% of exons had at least half the median depth of coverage. An analysis of reference SNPs revealed a sensitivity of up to 93% and a specificity of 98.2% or higher.

摘要

与非靶向测序相比,靶向下一代测序的序列捕获方法有望大幅降低基因组学项目的成本。然而,专门针对生物学相关基因组区域的评估捕获方法很少。全外显子组捕获已被证明是发现疾病遗传根源的有力工具,与非靶向全基因组测序相比,目标大小减少了>90 倍,因此计算测序能力也减少了>90 倍。为了进一步降低成本,一种有价值的补充方法是分析更小的、相关的基因子集,但需要涉及大量的样本。然而,由于富集系统的可扩展性有限,目标大小和样本数量的有效调整受到了阻碍。我们报告了一种高度可扩展和自动化的方法,使用微流控 DNA 阵列捕获 115 个与癌症相关基因的 480 Kb 外显子子集。该阵列可在没有条形码策略的情况下,从 125 Kb 到 1 Mb 的目标大小和/或 1 到 8 个样本之间进行适配,与全外显子组测序相比,计算测序能力进一步减少了 26 到 270 倍。对 HapMap 基因组进行 Illumina GAII 分析,发现该外显子子集的丰度>96%。均匀性如此之高,以至于>68%的外显子至少有一半的中位覆盖深度。对参考 SNP 的分析表明,敏感性高达 93%,特异性为 98.2%或更高。

相似文献

1
Targeted high throughput sequencing of a cancer-related exome subset by specific sequence capture with a fully automated microarray platform.通过使用全自动微阵列平台进行特定序列捕获,对癌症相关外显子亚组进行靶向高通量测序。
Genomics. 2010 Apr;95(4):241-6. doi: 10.1016/j.ygeno.2010.01.006. Epub 2010 Feb 6.
2
High-performance single-chip exon capture allows accurate whole exome sequencing using the Illumina Genome Analyzer.高通量单芯片外显子捕获可使用 Illumina Genome Analyzer 实现准确的全外显子组测序。
Sci China Life Sci. 2011 Oct;54(10):945-52. doi: 10.1007/s11427-011-4232-4. Epub 2011 Oct 29.
3
Massively parallel sequencing of ataxia genes after array-based enrichment.基于微阵列富集的共济失调基因的大规模平行测序。
Hum Mutat. 2010 Apr;31(4):494-9. doi: 10.1002/humu.21221.
4
Multiplex amplification of large sets of human exons.大量人类外显子的多重扩增。
Nat Methods. 2007 Nov;4(11):931-6. doi: 10.1038/nmeth1110. Epub 2007 Oct 14.
5
Array-based sequence capture and next-generation sequencing for the identification of primary immunodeficiencies.基于阵列的序列捕获和下一代测序用于原发性免疫缺陷的鉴定。
Scand J Immunol. 2012 Mar;75(3):350-4. doi: 10.1111/j.1365-3083.2011.02658.x.
6
Direct selection of human genomic loci by microarray hybridization.通过微阵列杂交直接选择人类基因组位点。
Nat Methods. 2007 Nov;4(11):903-5. doi: 10.1038/nmeth1111. Epub 2007 Oct 14.
7
Repeat subtraction-mediated sequence capture from a complex genome.重复减法介导的复杂基因组序列捕获。
Plant J. 2010 Jun 1;62(5):898-909. doi: 10.1111/j.1365-313X.2010.04196.x. Epub 2010 Mar 4.
8
Comparison of solution-based exome capture methods for next generation sequencing.基于溶液的外显子组捕获方法在下一代测序中的比较。
Genome Biol. 2011 Sep 28;12(9):R94. doi: 10.1186/gb-2011-12-9-r94.
9
Enabling technologies of genomic-scale sequence enrichment for targeted high-throughput sequencing.用于靶向高通量测序的基因组规模序列富集的使能技术。
Genomics. 2009 Dec;94(6):363-8. doi: 10.1016/j.ygeno.2009.08.012. Epub 2009 Aug 29.
10
Genome-wide in situ exon capture for selective resequencing.用于选择性重测序的全基因组原位外显子捕获
Nat Genet. 2007 Dec;39(12):1522-7. doi: 10.1038/ng.2007.42. Epub 2007 Nov 4.

引用本文的文献

1
Detecting likely germline variants during tumor-based molecular profiling.在基于肿瘤的分子谱分析过程中检测可能的种系变异。
J Clin Invest. 2025 Aug 1;135(15). doi: 10.1172/JCI190264.
2
Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.基于杂交捕获的下一代测序技术评估神经纤维瘤病1型(NF1)基因的编码序列和内含子深部突变
Genes (Basel). 2016 Dec 17;7(12):133. doi: 10.3390/genes7120133.
3
Drug discovery in advanced prostate cancer: translating biology into therapy.晚期前列腺癌的药物研发:将生物学转化为治疗方法。
Nat Rev Drug Discov. 2016 Oct;15(10):699-718. doi: 10.1038/nrd.2016.120. Epub 2016 Jul 22.
4
The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencing.安捷伦基于杂交捕获的靶向大规模平行测序所需的起始DNA最小量。
Sci Rep. 2016 May 25;6:26732. doi: 10.1038/srep26732.
5
Strategies for modern biomarker and drug development in oncology.肿瘤学中现代生物标志物与药物开发的策略
J Hematol Oncol. 2014 Oct 3;7:70. doi: 10.1186/s13045-014-0070-8.
6
Comprehensive molecular diagnosis of Bardet-Biedl syndrome by high-throughput targeted exome sequencing.通过高通量靶向外显子组测序对巴德-比埃尔综合征进行全面分子诊断。
PLoS One. 2014 Mar 7;9(3):e90599. doi: 10.1371/journal.pone.0090599. eCollection 2014.
7
Reinventing diagnostics for personalized therapy in oncology.为肿瘤学的个性化治疗重新定义诊断。
Cancers (Basel). 2010 Jun 2;2(2):1066-91. doi: 10.3390/cancers2021066.
8
Microfluidic chip-based technologies: emerging platforms for cancer diagnosis.微流控芯片技术:癌症诊断的新兴平台。
BMC Biotechnol. 2013 Sep 27;13:76. doi: 10.1186/1472-6750-13-76.
9
Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics.将个性化癌症基因组分析应用于临床:生物信息学面临的挑战。
Genome Med. 2012 Jul 30;4(7):61. doi: 10.1186/gm362. eCollection 2012.
10
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.通过靶向、大规模平行测序技术对临床肿瘤样本中的可操作基因组改变进行高通量检测。
Cancer Discov. 2012 Jan;2(1):82-93. doi: 10.1158/2159-8290.CD-11-0184. Epub 2011 Nov 7.